Home › Trial NCT02074878
CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer
- Trial IDNCT02074878
- StatusTerminated
- PhasePhase 1
- Study typeInterventional
- SponsorMothaffar Rimawi
- Enrollment3
- Start date2014-06
- ConditionsBreast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.